Listed

LENZ Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023

Filed with the SEC on Feb 27, 2024 and accepted by EDGAR at Feb 27, 2024, 16:11 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2023-01-01 to 2023-12-31$32.1mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2023-01-01 to 2023-12-31−$135.2mus-gaap:OperatingIncomeLoss
Net income12 months2023-01-01 to 2023-12-31−$124.7mus-gaap:NetIncomeLoss
Diluted EPS12 months2023-01-01 to 2023-12-31−$2.19us-gaap:EarningsPerShareDiluted
Basic EPS12 months2023-01-01 to 2023-12-31−$2.19us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2023-01-01 to 2023-12-3157,015,159 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2023-01-01 to 2023-12-31−$90.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2023-01-01 to 2023-12-31$10.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-12-31$184.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-12-31$188.0mus-gaap:AssetsCurrent
Total assetsAt period end2023-12-31$188.5mus-gaap:Assets
Current liabilitiesAt period end2023-12-31$4.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-12-31$4.9mus-gaap:Liabilities
Shareholders' equityAt period end2023-12-31$183.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-24-021135. Last ingested by Listed: Nov 5, 2026, 13:56 ET. Listed shows no prices and gives no investment advice.